RNA Targeting Small Molecule Drug Discovery Market Size Report, 2023-2032
The global RNA targeting small molecule drug discovery market size was exhibited at USD 1.19 billion in 2022 and is projected to hit around USD 7.44 billion by 2032, growing at a CAGR of 20.11% during the forecast period 2023 to 2032.
Key Pointers:
RNA Targeting Small Molecule Drug Discovery Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 1.43 Billion |
| Market Size by 2032 | USD 7.44 Billion |
| Growth Rate From 2023 to 203 | CAGR of 20.11% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Indication, End-user |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Accent Therapeutics; Anima Biotech Inc.; Arrakis Therapeutics; AstraZeneca; Epics Therapeutics; Expansion Therapeutics; Hoffmann-La Roche Ltd; H3 Biomedicine Inc.; PTC Therapeutics; Ribometrix; Servier Laboratories; Skyhawk Therapeutics, Inc |
The increasing demand for RNA targeted small molecule drugs due to their ability to target a broad range of diseases, such as cancer, neurological disorders, and genetic disorders, is expected to drive market growth. Additionally, advancements in RNA targeted drug discovery technologies and increased government funding for RNA research are also contributing to market growth. However, the high cost of drug development and the complexity of RNA based drug discovery are expected to hinder market growth to some extent.
The RNA targeting small molecules drug discovery industry is expected to transform the way the healthcare industry currently treats several diseases. These medications function by specifically targeting RNA molecules, which are appealing drug development targets since they are essential for controlling gene expression. Drugs that target RNA offer the potential to address conditions that have historically been challenging to treat with traditional medications. These include conditions that are caused by mutations in particular genes. Owing to the recently validated advantages of RNA-targeting small molecules, several companies are investing in this novel emerging field. There are several drug candidates in the pipeline, which are anticipated to be launched by 2024 and later.
The RNA targeting small molecules drug discovery industry promises a bright future. However, there are still several obstacles that pose a challenge to its growth. These include the exorbitant cost of medication research. This can reach billions of dollars and is one of the main obstacles. Creating RNA-targeted medications necessitates specialized knowledge and cutting-edge technology, which further raises the price of drug development. Moreover, it may be challenging to find prospective therapeutic candidates due to the intricacy of RNA-based drug discovery, which could add to the expense and length of time needed for drug development. Pharmaceutical corporations are heavily spending on research and development to address these issues, and they are collaborating with academic institutions and contract research groups to hasten the drug discovery and development process.
The COVID-19 pandemic had a mixed impact on the RNA targeting small molecules drug discovery industry. On the one hand, the pandemic has increased the demand for fresh approaches to treating viral illnesses, including those brought on by RNA viruses. By preventing viral RNA from replicating, RNA-targeted medications may be beneficial in treating viral infections. As a result, there is now more interest in developing RNA-targeted medicines to treat COVID-19 and other viral infections.
On the other hand, the pandemic has also hampered efforts to create new drugs because numerous academic institutions and pharmaceutical firms had to transfer funding to COVID-19 research. This has caused funding issues for non-COVID-19 drug discovery initiatives as well as delays in the development of RNA-targeted medications for other disorders. Timelines for drug development have been considerably extended as a result of supply chains and clinical studies being affected by the epidemic. To overcome the challenges posed by the COVID-19 pandemic, pharmaceutical companies have had to adapt and innovate in several ways. One recent example is the partnership between AstraZeneca and the University of Oxford to develop and distribute a COVID-19 vaccine. This partnership involved a collaborative effort to develop a vaccine that was both effective and scalable, which required the use of innovative technologies and processes.
Some of the prominent players in the RNA Targeting Small Molecule Drug Discovery Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global RNA Targeting Small Molecule Drug Discovery market.
By Indication
By End-user
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Scope
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Nova One Advisor internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
Chapter 3. RNA-targeting Small Molecule Drug Discovery Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing pipeline of RNA-targeting small molecules drugs
3.2.1.2. Increasing private and public funding for the discovery and development of RNA-targeting small-molecule drugs
3.2.1.3. Growing prevalence of cancer and neurological disorders to boost the demand for novel RNA-targeting small molecules drugs
3.2.2. Market restraint analysis
3.2.2.1. High cost of drug development and the complexity of RNA-based drug discovery is expected to hinder the market growth
3.2.2.2. Comparatively low awareness in developing economies about RNA-targeting small molecules
3.3. RNA Targeting Small Molecule Drug Discovery: Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Major Deals & Strategic Alliances Analysis
3.3.4. COVID-19 Impact Analysis
Chapter 4. RNA-targeting Small Molecule Drug Discovery Market: Indication Estimates &Trend Analysis
4.1. Definitions and Scope
4.2. RNA-targeting Small Molecule Drug Discovery: Indication Market Share, 2023 2032
4.2.1. Cancer
4.2.1.1. Cancer Market, 2020 - 2032
4.2.2. Infectious Diseases
4.2.2.1. Infectious Diseases Market, 2020 - 2032
4.2.3. Metabolic Diseases
4.2.3.1. Metabolic Diseases
4.2.4. Neurological Diseases
4.2.4.1. Neurological Disease Market, 2020 - 2032
4.2.5. Others
4.2.5.1. Others Market, 2020 - 2032
Chapter 5. RNA-targeting Small Molecule Drug Discovery Market: End User Segment Estimates & Trend Analysis
5.1. Definitions and Scope
5.2. RNA-targeting Small Molecule Drug Discovery Market: End-User Market Share Analysis, 2021 & 2032
5.2.1. Pharmaceutical and Biopharmaceutical Companies
5.2.1.1. Synthetic Market, 2020 - 2032
5.2.2. Academic and Research Institutes
5.2.2.1. Academic and Research Institutes Market, 2020 - 2032
5.2.3. Others
5.2.3.1. Others Market, 2020 - 2032
Chapter 6. RNA-targeting Small Molecule Drug Discovery Market: Regional Analysis
6.1. Healthcare Finance Solutions: Regional market share analysis, 2021 & 2032
6.2. North America
6.2.1. North America Market estimates and forecast, 2020 - 2032
6.2.2. U.S.
6.2.2.1. U.S. Market estimates and forecast, 2020 - 2032
6.2.3. Canada
6.2.3.1. Canada Market estimates and forecast, 2020 - 2032
6.3. Europe
6.3.1. Europe Market estimates and forecast, 2020 - 2032
6.3.2. U.K.
6.3.2.1. U.K. Market estimates and forecast, 2020 - 2032
6.3.3. Germany
6.3.3.1. Germany Market estimates and forecast, 2020 - 2032
6.3.4. France
6.3.4.1. France Market estimates and forecast, 2020 - 2032
6.3.5. Italy
6.3.5.1. Italy Market estimates and forecast, 2020 - 2032
6.3.6. Spain
6.3.6.1. Spain Market estimates and forecast, 2020 - 2032
6.3.7. Denmark
6.3.7.1. Denmark Market estimates and forecast, 2020 - 2032
6.3.8. Sweden
6.3.8.1. Sweden Market estimates and forecast, 2020 - 2032
6.3.9. Norway
6.3.9.1. Norway Market estimates and forecast, 2020 - 2032
6.4. Asia Pacific
6.4.1. Asia Pacific Market estimates and forecast, 2020 - 2032
6.4.2. Japan
6.4.2.1. Japan Market estimates and forecast, 2020 - 2032
6.4.3. China
6.4.3.1. China Market estimates and forecast, 2020 - 2032
6.4.4. India
6.4.4.1. India Market estimates and forecast, 2020 - 2032
6.4.5. Thailand
6.4.5.1. Thailand Market estimates and forecast, 2020 - 2032
6.4.6. South Korea
6.4.6.1. South Korea Market estimates and forecast, 2020 - 2032
6.4.7. Australia
6.4.7.1. Australia Market estimates and forecast, 2020 - 2032
6.5. Latin America
6.5.1. Latin America Market estimates and forecast, 2020 - 2032
6.5.2. Brazil
6.5.2.1. Brazil Market estimates and forecast, 2020 - 2032
6.5.3. Mexico
6.5.3.1. Mexico Market estimates and forecast, 2020 - 2032
6.5.4. Argentina
6.5.4.1. Argentina Market estimates and forecast, 2020 - 2032
6.6. MEA
6.6.1. South Africa
6.6.1.1. South Africa Market estimates and forecast, 2020 - 2032
6.6.2. Saudi Arabia
6.6.2.1. Saudi Arabia Market estimates and forecast, 2020 - 2032
6.6.3. UAE
6.6.3.1. UAE Market estimates and forecast, 2020 - 2032
6.6.4. Kuwait
6.6.4.1. Kuwait Market estimates and forecast, 2020 - 2032
Chapter 7. Competitive Landscape
7.1. Company Profiles
7.1.1. Accent Therapeutics
7.1.1.1. Company overview
7.1.1.2. Financial Performance
7.1.1.3. Service benchmarking
7.1.1.4. Strategic initiatives
7.1.2. Anima Biotech Inc.
7.1.2.1. Company overview
7.1.2.2. Financial performance
7.1.2.3. Service benchmarking
7.1.2.4. Strategic initiatives
7.1.3. Arrakis Therapeutics
7.1.3.1. Company overview
7.1.3.2. Financial performance
7.1.3.3. Service benchmarking
7.1.3.4. Strategic initiatives
7.1.4. AstraZeneca
7.1.4.1. Company overview
7.1.4.2. Financial performance
7.1.4.3. Service benchmarking
7.1.4.4. Strategic initiatives
7.1.5. Epics Therapeutics
7.1.5.1. Company overview
7.1.5.2. Financial performance
7.1.5.3. Service benchmarking
7.1.5.4. Strategic initiatives
7.1.6. Expansion Therapeutics
7.1.6.1. Company overview
7.1.6.2. Financial performance
7.1.6.3. Service benchmarking
7.1.6.4. Strategic initiatives
7.1.7. Hoffmann-La Roche Ltd
7.1.7.1. Company overview
7.1.7.2. Financial performance
7.1.7.3. Service benchmarking
7.1.7.4. Strategic initiatives
7.1.8. H3 Biomedicine Inc.
7.1.8.1. Company overview
7.1.8.2. Financial performance
7.1.8.3. Service benchmarking
7.1.8.4. Strategic initiatives
7.1.9. PTC Therapeutics.
7.1.9.1. Company overview
7.1.9.2. Financial performance
7.1.9.3. Service benchmarking
7.1.9.4. Strategic initiatives
7.1.10. Ribometrix
7.1.10.1. Company overview
7.1.10.2. Financial performance
7.1.10.3. Service benchmarking
7.1.10.4. Strategic initiatives
7.1.11. Servier Laboratories
7.1.11.1. Company overview
7.1.11.2. Financial performance
7.1.11.3. Service benchmarking
7.1.11.4. Strategic initiatives
7.1.12. Skyhawk Therapeutics, Inc.
7.1.12.1. Company overview
7.1.12.2. Financial performance
7.1.12.3. Service benchmarking
7.1.12.4. Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers